Rigel Pharmaceuticals, Inc. (RIGL)
The price, the headline numbers and the latest news, in one place.
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, Analysis & Data
| Bid | 41.6 |
| Market Cap | 906M |
| Revenue (ttm) | 277M |
| Net Income (ttm) | 322M |
| 1.17 | |
| 16.53 | |
| 2.93 | |
| 9.82 | |
| P/B (ttm) | 2.13 |
| P/S (ttm) | 3.24 |
| Earnings Date | Mar 5, 2024 |
| Ask | 54 |
| Volume | 190,375 |
| Avg. Volume (20D) | 351,325 |
| Open | 49.51 |
| Previous Close | 49.42 |
| Day's Range | 48.09 - 49.90 |
| 52-Week Range | 24.95 - 52.24 |
| Analyst | n/a |
| Price Target | 55 (13.4%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML...
Financial Performance
In 2025, Rigel Pharmaceuticals's revenue was 294.28M, an increase of 64.15% compared to the previous year's 179.28M. Earnings were 367.02M, an increase of 1,999.08%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for RIGL stock is "null". The 12-month stock price forecast is 55, which is upside of 13.4% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $78.7M misses estimates by $0, with -22.60% YoY decline.
- EPS of 0.88 exceeds estimates by 0.96, with -73.17% YoY decline.
Analysts project revenue of ... Upgrade
